Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Maggiolo

Showing results (81-90 of 150) with videos related to

Pageof 15
Sort By:
Plos One|October 8, 2016
Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticeSilvia Costarelli, Alessandro Cozzi-Lepri, Giuseppe Lapadula, et al.
The Journal of Antimicrobial Chemotherapy|May 27, 2005
Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER CohortCarlo Torti, Franco Maggiolo, Andrea Patroni, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 10, 2011
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohortFabio Vescini, Alessandro Cozzi-Lepri, Marco Borderi, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2025
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIVLucia Taramasso, Stefano Bonora, Antonella Cingolani, et al.
Journal of the International AIDS Society|January 22, 2019
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohortAnnalisa Mondi, Alessandro Cozzi-Lepri, Alessandro Tavelli, et al.
AIDS (London, England)|February 3, 2021
Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U eraGiordano Madeddu, Andrea De Vito, Alessandro Cozzi-Lepri, et al.
Plos One|May 29, 2015
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAARTGiuseppe Lapadula, Liliane Chatenoud, Andrea Gori, et al.
Journal of the International AIDS Society|November 15, 2014
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in ItalyAlessandro Cozzi-Lepri, Sergio Lo Caputo, Franco Maggiolo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 14, 2009
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosisAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Antonella Castagna, et al.
Antiviral Therapy|March 26, 2004
Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptionsAndrea Foli, Renato Maserati, Gabriele Barasolo, et al.
Pageof 15

Showing results (81-90 of 150) with videos related to

Sort By:
Pageof 15
Plos One|October 8, 2016
Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticeSilvia Costarelli, Alessandro Cozzi-Lepri, Giuseppe Lapadula, et al.
The Journal of Antimicrobial Chemotherapy|May 27, 2005
Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER CohortCarlo Torti, Franco Maggiolo, Andrea Patroni, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 10, 2011
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohortFabio Vescini, Alessandro Cozzi-Lepri, Marco Borderi, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2025
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIVLucia Taramasso, Stefano Bonora, Antonella Cingolani, et al.
Journal of the International AIDS Society|January 22, 2019
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohortAnnalisa Mondi, Alessandro Cozzi-Lepri, Alessandro Tavelli, et al.
AIDS (London, England)|February 3, 2021
Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U eraGiordano Madeddu, Andrea De Vito, Alessandro Cozzi-Lepri, et al.
Plos One|May 29, 2015
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAARTGiuseppe Lapadula, Liliane Chatenoud, Andrea Gori, et al.
Journal of the International AIDS Society|November 15, 2014
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in ItalyAlessandro Cozzi-Lepri, Sergio Lo Caputo, Franco Maggiolo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 14, 2009
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosisAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Antonella Castagna, et al.
Antiviral Therapy|March 26, 2004
Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptionsAndrea Foli, Renato Maserati, Gabriele Barasolo, et al.
Pageof 15